We achieved record-high net sales and operating income. Additionally, acquisition activities enhanced our pipeline in the areas of Psychiatry & Neurology, as well as Oncology, while we made strategic growth investments for when the exclusivity period of LATUDA® expires.

Snapshot 2016

From April 2015, we started a ONE TEAM operating structure for the Global Clinical Development (GCD) organization, which unifies Sumitomo Dainippon Pharma and Sunovion Pharmaceuticals Inc. Under this cooperative structure, we are pursuing GCD that allows simultaneous new drug application submission in Japan and the U.S., while accelerating development of late-stage development products.
LATUDA®, which grew into a blockbuster drug surpassing annual sales of US$ 1 billion in North America in fiscal 2015, continued to post strong results in fiscal 2016, recording sales of US$ 1.25 billion. This was a new record high for sales.

Enhanced pipeline from acquisitions and in-licensing

The acquisition of Cynapsus Therapeutics Inc. (Canada) added to our pipeline sublingual apomorphine hydrochloride, under development as a treatment for OFF episodes associated with Parkinson’s disease, and the acquisition of Tolero Pharmaceuticals, Inc. (U.S.) added alvocidib, under development as a hematologic malignancies treatment. We aim to bring these compounds to market in fiscal 2018–2019.

Additionally, Sunovion Pharmaceuticals Inc. entered into an exclusive license agreement with Novartis for the U.S. commercialization rights to three treatments for chronic obstructive pulmonary disease (COPD).
Contributing
to global health

We participate in “Access Accelerated”, the first global partnership activity among global pharmaceutical companies to improve access to healthcare in developing countries. The partnership is focused on improving access to prevention, treatment, and care of non-communicable diseases (NCDs), such as cancers and cardiovascular diseases, in low- and middle-income countries where nearly 80% of NCD-related deaths occur.

http://www.accessaccelerated.org/
Enhancing programs supporting work-life balance

In October 2015, we introduced a Paternity and Child Care Leave System for men (dubbed “Good Daddy Leave”). In order to encourage men to participate in child care, the new system allows male employees to take up to five days of leave during the period up until their child turns one. The system, which is easy to use and allows non-contiguous days off, has a 100% utilization rate among eligible employees (during the period from October 2015 to the end of March 2017).

Achieved record-high net sales and operating income

North American income for LATUDA®, BROVANA®, and APTIOM® all made strong gains. In Japan, the strategic products AIMIX®, TRERIEF®, and Trulicity® showed steady results and we achieved record highs for Group net sales and operating income in fiscal 2016.